The fund focuses on companies driving advances in genomics, investing at least 80% of its assets in stocks from industries such as healthcare, technology, energy, and consumer goods. It trades on an exchange like a regular stock and is actively managed, meaning its managers make ongoing decisions about which companies to buy and sell. Because it concentrates its holdings rather than spreading them broadly, it carries a higher level of risk than a typical diversified fund.
